Triple-negative breast cancer (TNBC) poses a therapeutic challenge due to its aggressive nature and lack of targeted therapies. Epigenetic modifications contribute to TNBC tumorigenesis and drug resistance, offering potential therapeutic targets. Recent advancements in three-dimensional (3D) organoid cultures, enabling precise drug screening, hold immense promise for identifying novel compounds targeting TNBC. In this study, we established two patient-derived TNBC organoids and implemented a high-throughput drug screening system using these organoids and two TNBC cell lines. Screening a library of 169 epigenetic compounds, we found that organoid-based systems offer remarkable precision in drug response assessment compared to cell-based models. The top 30 compounds showing the highest drug sensitivity in the initial screening were further assessed in a secondary screen. Four compounds, panobinostat, pacritinib, TAK-901, and JIB-04, targeting histone deacetylase, JAK/STAT, histone demethylases, and aurora kinase pathways, respectively, exhibited potent anti-tumor activity in TNBC organoids, surpassing the effect of paclitaxel. Our study highlights the potential of these novel epigenetic drugs as effective therapeutic agents for TNBC and demonstrates the valuable role of patient-derived organoids in advancing drug discovery.
7 August 2024 in Clinical and Translational Medicine
Subnuclear compartmentalization has emerged as a critical determinant of transcriptional homeostasis and cell-fate determination. The nucleolus scaffolds specialized heterochromatin, yet the mechanisms orchestrating its spatial assembly and therapeutic relevance remain elusive. Here we identify the nucleolar deubiquitinase OTUD4 as a key coordinator of heterochromatin architecture. We demonstrate that casein kinase II (CK2)-mediated phosphorylation serves as a molecular switch to activate OTUD4, which functions as a phospho-activated, K63-specific deubiquitinase. Crucially, we show that the spatial anchoring of H3K9me3-marked heterochromatin to the nucleolar surface is molecularly mandated by the K63-linked ubiquitination status of Nucleophosmin (NPM1) at the Lys27 (K27) residue. OTUD4-mediated deubiquitination of NPM1 K27 is indispensable for stabilizing the NPM1 pentameric scaffold, which in turn sequesters H3K9me3-marked domains at the nucleolar periphery. Disruption of the CK2–OTUD4–NPM1 axis triggers heterochromatin detachment, eliciting nucleolar stress and retroelement derepression. This epigenetic collapse activates cytosolic DNA-sensing pathways to potentiate tumor-intrinsic immunogenicity. Clinically, an OTUD4-nucleolus gene signature correlates with adverse survival and immunotherapy resistance. Together, these findings establish a phosphorylation–deubiquitination cascade to preserve heterochromatin topology and nominate spatial epigenetic targeting as a translational strategy to overcome immune evasion in refractory malignancies.
Subnuclear compartmentalization is a foundational determinant of transcriptional homeostasis and cell fate. The nucleolus serves as a scaffold for specialized heterochromatin, yet the mechanisms orchestrating their spatial assembly in malignant contexts remain elusive. Here we identify the nucleolar deubiquitinase OTUD4 as a key regulator of perinucleolar heterochromatin architecture in tumor cells. Casein kinase II (CK2)-mediated phosphorylation activates OTUD4 to specifically remove K63-linked ubiquitin chains from nucleophosmin (NPM1) at lysine 27. This deubiquitination is indispensable for stabilizing the pentameric NPM1 structural scaffold, thereby anchoring H3K9me3-marked heterochromatin to nucleolus. Disruption of the CK2–OTUD4–NPM1 axis in tumor cells triggers heterochromatin detachment, eliciting nucleolar stress and retroelement derepression. This topological collapse activates cytosolic DNA-sensing pathways to potentiate tumor-intrinsic immunogenicity. Clinically, an OTUD4-nucleolus gene signature correlates with adverse survival and immunotherapy resistance in patients with cancer. Collectively, targeting this signal-responsive spatial architecture offers a therapeutic strategy to overcome immune evasion in refractory malignancies.